Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model.
2008 (English)In: Journal of Neuro-Oncology, ISSN 0167-594X, E-ISSN 1573-7373, Vol. 88, no 1, 1-9 p.Article in journal (Refereed) Published
AIM OF THE STUDY:
The extensive neovascularisation of malignant glioma is mainly influenced by vascular endothelial growth factor (VEGF). The effect of ZD6474, a potent inhibitor of VEGF-receptor-2, was evaluated in combination with either radiotherapy or temozolomide.
The effects on glioma growth were investigated in the intracerebral BT4C rat glioma model. ZD6474 30 mg/kg was given alone or in combination with radiotherapy 12 Gy x 1 or with temozolomide 100 mg/kg for 3 days. Two different experiments were performed comparing ZD6474 to radiotherapy or temozolomide. For each experiment 28 animals were randomized into four groups.
ZD6474 in combination with radiotherapy significantly decreased tumour area by 66% compared with controls whereas the combination with temozolomide decreased tumour area by 74%.
ZD6474 in combination with two standard modalities in the treatment of malignant glioma, radiotherapy and chemotherapy, markedly decreased the growth of an intracerebral experimental glioma. These results justify further investigations of these therapies in combination.
Place, publisher, year, edition, pages
2008. Vol. 88, no 1, 1-9 p.
Angiogenesis, Glioma, Radiotherapy, Temozolomide, VEGF, ZD6474
IdentifiersURN: urn:nbn:se:umu:diva-9545DOI: doi:10.1007/s11060-008-9527-3PubMedID: 18228115OAI: oai:DiVA.org:umu-9545DiVA: diva2:149216